Clinical Trial Update: Efficacy and Safety of BC-819 and Gemcitabine in Patients With Locally Advanced Pancreatic Adenocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BC-819 (a therapeutic DNA plasmid) with gemcitabine in locally advanced pancreatic adenocarcinoma was terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreas
• Pancreatic Adenocarcinoma

Drugs mentioned

• BC-819 (null)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Anchiano Therapeutics Israel Ltd. | Conditions: Pancreas, Adenocarcinoma | Phase 2 | Status: TERMINATED | Results posted: 2019-11-01